Aimed Alliance Releases 2020 Annual Report
In 2020, Aimed Alliance engaged in a wide array of activities to protect and enhance…
Browsing: Advocacy
Aimed Alliance Submits Comments to FDA / FTC on Competitive Marketplace for Biosimilars
On March 9, 2020, the U.S. Food and Drug Administration (FDA) and the Federal Trade…
Aimed Alliance Releases Position Statement on Cannabidiol (CBD)
On March 30, 2020, Aimed Alliance published a position statement on products containing cannabidiol (CBD).…
Aimed Alliance Joins Sign-On Letter Supporting the Federal Safe Step Act
On March 6, 2020, the National Psoriasis Foundation delivered a sign-on letter to the House…
Aimed Alliance Joins Sign-on Letter Supporting Passage of Kentucky Copay Accumulator Legislation
On March 11, 2020, Aimed Alliance joined a coalition of patient advocacy groups and provider…
Aimed Alliance Leads Sign-on Letter to HealthPartners, Cautioning Against Nonmedical Switching Practices
On March 9, 2020, Aimed Alliance sent a sign-on letter to HealthPartners, which is a…
Kentucky Banking and Insurance Committee Passes Copay Accumulator Bill
On March 4, 2020, Kentucky HB 72, a bill that would limit the use of…
Aimed Alliance Responds to the Administration’s Notice of Benefit and Payment Parameters for 2021
On January 31, 2020, the Centers for Medicare & Medicaid Services (CMS) released the proposed…
Aimed Alliance Releases 2019 Annual Report
Aimed Alliance experienced significant growth in 2019, and we are excited to share our progress…
Aimed Alliance Opposes Oregon Legislation that Could Restrict Access to Dialysis
On January 27, 2020, Oregon legislators introduced HB 4114, which would set physician payment rates…